Entrada Therapeutics, Inc. TRDA
Regular-session close
After hours · Nov 19, 4:26 PM ET
- YTD
- -54.86%
- 1 year
- -46.85%
- Market cap
- 181.66M
- Revenue (ttm)
- 215.23M
- Profit margin
- 25.53%
- EPS (ttm)
- -3.84
- Shares out
- 37.42M
- Forward P/E
- -5.54
- YTD return
- -54.86%
- 1-year return
- -46.85%
- Volume
- 341.09K
- Avg volume
- 396.49K
- Open
- 5.17
- Previous close
- 5.03
- Day's range
- 4.59 – 5.34
- 52-week range
- 4.11 – 16.45
- Beta
- -0.27
- Price target
- 26.43 (+469.6%)
Key statistics
- 50-day average
- 18.48
- 200-day average
- 15.77
- Enterprise value
- 234.75M
- Price / sales
- 3.04
- Price / book
- 1.46
- Revenue growth
- -55.30%
- Free cash flow
- -29.26M
- Total cash
- 449.34M
- Total debt
- 61.31M
- Return on equity
- 16.42%
- Short % of float
- 6.53%
Fundamental scorecard
4 of 25 checks passed on TRDA’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.67 | -0.35 | +0.32 | +47.76% |
| Aug 13, 2024 | Jun 1, 2024 | 0.65 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.65 | 1.55 | +0.90 | +138.46% |
| May 7, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.38 | 0.68 | +1.06 | +278.95% |
| Mar 13, 2024 | Dec 1, 2023 | -0.07 | -0.29 | -0.22 | -314.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 6, 2024 | Oppenheimer | main | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 26, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- entradatx.com
News
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $13
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study Entrada Therapeutics Q3 EPS $(0.94) Beats $(1.01) Estimate, Sales $905.000K Miss $5.871M Estimate
Your note
Sign in to keep a note on TRDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DOSHI DIPAL | Chief Executive Officer | Sale | Jul 14, 2024 | 334,475 |
| DOWDEN NATHAN J | President | Sale | Sep 25, 2024 | 125,149 |
| KIM PETER S | Director | Conversion of Exercise of derivative security | Jun 2, 2024 | 104,330 |
| KREHER NERISSA C | Officer | Sale | Sep 5, 2023 | 40,037 |
| SETHURAMAN NATARAJAN | Officer | Sale | Dec 2, 2024 | 144,997 |
| WENTWORTH KORY JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Dec 1, 2024 | 73,849 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 13.00% | 4,865,819 | 84.96M | Sep 29, 2024 |
| MPM Asset Management, LLC | 11.83% | 4,425,784 | 77.27M | Sep 29, 2024 |
| 5AM Venture Management, LLC | 11.78% | 4,408,379 | 76.97M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 8.15% | 3,049,572 | 53.25M | Sep 29, 2024 |
| Blackrock Inc. | 4.87% | 1,822,835 | 31.83M | Sep 29, 2024 |
| FMR, LLC | 4.66% | 1,743,498 | 30.44M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 5.19% | 1,942,377 | 33.91M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.81% | 677,414 | 11.83M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.70% | 634,828 | 11.08M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.20% | 449,109 | 7.84M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 0.96% | 357,801 | 6.25M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 0.83% | 309,169 | 5.40M | Oct 30, 2024 |
